Cite
Soluble CD137 and risk of hepatocellular carcinoma: nested case–control studies in cohorts in Shanghai and Singapore.
MLA
Thomas, Claire E., et al. “Soluble CD137 and Risk of Hepatocellular Carcinoma: Nested Case–control Studies in Cohorts in Shanghai and Singapore.” British Journal of Cancer, vol. 128, no. 11, June 2023, pp. 2081–88. EBSCOhost, https://doi.org/10.1038/s41416-023-02223-z.
APA
Thomas, C. E., Adibi, J. J., Kuipers, A. L., Diergaarde, B., Luu, H. N., Jin, A., Koh, W.-P., Gao, Y.-T., Adams-Haduch, J., Wang, R., Lokshin, A., Behari, J., & Yuan, J.-M. (2023). Soluble CD137 and risk of hepatocellular carcinoma: nested case–control studies in cohorts in Shanghai and Singapore. British Journal of Cancer, 128(11), 2081–2088. https://doi.org/10.1038/s41416-023-02223-z
Chicago
Thomas, Claire E., Jennifer J. Adibi, Allison L. Kuipers, Brenda Diergaarde, Hung N. Luu, Aizhen Jin, Woon-Puay Koh, et al. 2023. “Soluble CD137 and Risk of Hepatocellular Carcinoma: Nested Case–control Studies in Cohorts in Shanghai and Singapore.” British Journal of Cancer 128 (11): 2081–88. doi:10.1038/s41416-023-02223-z.